Global Regulatory Considerations (FDA and EU MDR/IVDR)

Global regulatory strategy for life sciences products must account for FDA requirements alongside EU MDR or IVDR when devices and diagnostics are in scope, and with regional drug pathways when pharmaceuticals or biologics are involved. Differences in classification, clinical evidence, quality system expectations, and post-market duties change sequence, budget, and labeling. Treating regions as copy-paste exercises creates rework and conflicting claims that surface late in review or after launch.

Viltis helps teams build coherent multi-region plans. We compare pathway options, identify where evidence can be shared, and flag where U.S. and EU expectations diverge enough to need separate studies, files, or post-market systems. For combination programs we help you decide launch order, Notified Body timing relative to FDA review, and how CMC or design history files should be structured for dual use without forcing one region’s template onto the other in ways that weaken both packages.

Our role is advisory and operational support inside your organization. We do not issue certificates, act as a Notified Body, or replace your legal manufacturer or sponsor responsibilities. We do help you keep one living regulatory map that leadership, clinical, quality, and commercial can follow as timelines, evidence, and regional priorities shift over a multi-year development plan.

Global plans also fail when affiliates invent local interpretations without a central decision record. Shared pathway memos and claim matrices keep regional teams from promising labels or studies the core dossier cannot support, and they give new hires a clear picture of why the U.S. and EU paths were sequenced the way they were. When budgets force a single first market, we help you document what evidence will still be needed for the second region so the first-region package is not written in a way that blocks later reuse or forces a full redo of clinical work.

Global regulatory considerations often address

• FDA versus EU MDR/IVDR pathway and evidence comparisons
• Shared clinical and performance data strategies across regions
• Launch sequencing and dependency planning
• Labeling and claims consistency across markets
• Post-market surveillance and vigilance alignment
• Quality system intersections (for example QMSR/ISO 13485 with MDR)
• Resource and vendor planning for dual-region submissions

International programs succeed when regional differences are explicit from the start. Viltis helps you write that plan clearly so global expansion does not surprise you mid-development or mid-remediation.